A Longitudinal Neuropsychological Study of Partial Brain Radiation in Adults with Brain Tumors
Affiliations
Objective: To investigate longitudinal cognitive functioning in patients with brain tumor treated with modern highly conformal fractionated partial brain radiation therapy (RT).
Methods: Seventeen (of 22 initial consecutive patients) adults with primarily low-grade brain neoplasms who underwent either biopsy or tumor resection were tested at pre-RT baseline and at 3, 6, 12, and 24 months after baseline. Participants were classified as RT-treated nonprogressors (n = 12) or progressors (n = 3) based on serial follow-up structural imaging. Two patients received surgery only and served as controls to help minimize surgical, practice, test form, or other potential non-RT effects. Serial neuropsychological assessments were conducted using alternate forms of the Selective Reminding Test, 10/36 Spatial Recall Test, and Symbol Digit Modality Test (oral, written) as well as the Shipley Scale (baseline only), Wechsler Adult Intelligence Scale-Revised Digit Span, Trail Making Test, and the Symptom Checklist-90-Revised Global Severity Index scale.
Results: There was evidence of subtle attention and memory improvement in RT-treated nonprogressors throughout the 2-year period, with no evidence of cognitive decline. In contrast, patients with disease progression evidenced more substantial decline in memory and attention.
Conclusions: Partial brain fractionated RT was not associated with adverse neuropsychological effects through the first 2 years following therapy.
Kotecha R, Schiff D, Chakravarti A, Fleming J, Brown P, Puduvalli V J Clin Oncol. 2024; 42(21):2588-2598.
PMID: 38833641 PMC: 11283772. DOI: 10.1200/JCO.23.02195.
Jabehdar Maralani P, Stewart J, Hiremath S, Lawrence L, Chan R, Lau A J Neurooncol. 2023; 164(3):597-605.
PMID: 37707752 DOI: 10.1007/s11060-023-04440-1.
Pertz M, Schlomer S, Seidel C, Hentschel B, Loffler M, Schackert G J Neurooncol. 2023; 164(2):353-366.
PMID: 37648934 PMC: 10522752. DOI: 10.1007/s11060-023-04419-y.
Bevacizumab in real-life patients with recurrent glioblastoma: benefit or futility?.
Smolenschi C, Rassy E, Pallud J, Dezamis E, Copaciu R, Parker F J Neurol. 2023; 270(5):2702-2714.
PMID: 36813928 DOI: 10.1007/s00415-023-11600-w.
Cognitive outcomes after multimodal treatment in adult glioma patients: A meta-analysis.
De Roeck L, Gillebert C, van Aert R, Vanmeenen A, Klein M, Taphoorn M Neuro Oncol. 2023; 25(8):1395-1414.
PMID: 36809489 PMC: 10398801. DOI: 10.1093/neuonc/noad045.